{"altmetric_id":7562353,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Mallinckrodt"],"first_seen_on":"2016-05-17T20:02:19+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1463529600,"links":["https:\/\/clinicaltrials.gov\/show\/NCT02633046"],"nct_id":"NCT02633046","pubdate":"2015-12-15T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS (PODOCYTE)","type":"clinical_trial_study_record"},"altmetric_score":{"score":535,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":535},"context_for_score":{"all":{"total_number_of_other_articles":7711702,"mean":6.6147835493025,"rank":5972,"this_scored_higher_than_pct":99,"this_scored_higher_than":7705690,"rank_type":"exact","sample_size":7711702,"percentile":99},"similar_age_3m":{"total_number_of_other_articles":269246,"mean":11.541852966628,"rank":705,"this_scored_higher_than_pct":99,"this_scored_higher_than":268541,"rank_type":"exact","sample_size":269246,"percentile":99},"this_journal":{"total_number_of_other_articles":20904,"mean":10.090806582787,"rank":37,"this_scored_higher_than_pct":99,"this_scored_higher_than":20867,"rank_type":"exact","sample_size":20904,"percentile":99},"similar_age_this_journal_3m":{"total_number_of_other_articles":987,"mean":13.206870182556,"rank":2,"this_scored_higher_than_pct":99,"this_scored_higher_than":985,"rank_type":"exact","sample_size":987,"percentile":99}}},"demographics":[],"counts":{"total":{"posts_count":69},"news":{"unique_users_count":69,"unique_users":["sys_con_media","stock_nod_quotes","ticker_tech","nasdaq","minyanville_finance","wand_17","wtol","nbc12","kten","benzinga","bioportfolio","yahoo_finance_usa","kx_news","wtvm","nbc_right_now_kndu_25","stockhouse","ariva","yahoo_finance_singapore","fox_wilmington","kfve_the_home_team","fox_14_news","newswest9","wlox","kusi_news","newson6","wltz","noodls","klkn_tv_eyewitness_news","wistv","abc_6_news_wlne","wdam_tv","kuam","cleveland_19","kltv","cw_richmond","wboc_16","kplc_7_news","48_waff","kceng12","wflx_fox_29","ksla_news_12","cbs8","wrcb_tv","wsfa","erie_news_now","14_news","wdrb","news_channel","12_news_kbmt","khq","biotech_gate","kait_tv","hawaii_news_now","ktre","mississippi_news_now","wmbf_news","kiiitv_3","abc_40","wfmj","walb","south_carolina_news_now","wtoc","wmc_action_news_5","wave_3_news","2_news","news_channel_6","abc_7_news_kswo","news_9","biospace"],"posts_count":69}},"posts":{"news":[{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565049795&p=1pl&v=1&x=NJUp1EYpqWx83R2IJE6Wow","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:01:25+00:00","summary":"_ CHESTERFIELD, United Kingdom \"This study is expected to be the largest controlled FSGS-focused clinical trial conducted to date,\" said lead investigator James A.","author":{"name":"SYS-CON Media","url":"http:\/\/www.sys-con.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/756\/normal\/Screen_Shot_2016-01-26_at_16.29.38.png?1453825803"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565010952&p=1pl&v=1&x=M8kw8Lsqu9rbWA3DOa4dMw","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:01:00+00:00","summary":"CHESTERFIELD, United Kingdom \"This study is expected to be the largest controlled FSGS-focused clinical trial conducted to date,\" said lead investigator James A.","author":{"name":"Stock Nod: Quotes","url":"http:\/\/quotes.stocknod.com\/stocknod","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/671\/normal\/Screen_Shot_2016-01-26_at_13.59.47.png?1453816868"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26564971559&p=1pl&v=1&x=Gox6jKV7zAzV9uSkqE_OhQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:02:01+00:00","summary":"\/PRNewswire\/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P.","author":{"name":"Ticker Tech","url":"http:\/\/www.tickertech.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/724\/normal\/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565008685&p=1pl&v=1&x=dJn92GaPQmpFwn_jX8ZXGA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T08:01:00+00:00","summary":"\/PRNewswire\/ -- Mallinckrodt plc (NYSE:MNK), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P.","author":{"name":"NASDAQ","url":"http:\/\/www.nasdaq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/839\/normal\/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565009096&p=1pl&v=1&x=AogRM-ieCRh-gz5sqBIzUg","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:01:00+00:00","summary":"CHESTERFIELD, United Kingdom, May 17, 2016 \/PRNewswire\/ -- Mallinckrodt plc ( NYSE: MNK ), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the\u2026","author":{"name":"Minyanville: Finance ","url":"http:\/\/finance.minyanville.com\/minyanville","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/637\/normal\/Screen_Shot_2016-02-02_at_16.44.51.png?1454431502"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565012842&p=1pl&v=1&x=v78m-MzZdi2TJZUqcaBZDA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WAND 17","url":"http:\/\/www.wandtv.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/694\/normal\/Screen_Shot_2016-01-26_at_14.41.02.png?1453819294"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565019171&p=1pl&v=1&x=P3BsAtSt8Im6xViT9KaNrQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WTOL","url":"http:\/\/www.wtol.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/662\/normal\/Screen_Shot_2016-01-26_at_12.19.14.png?1453810785"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565022244&p=1pl&v=1&x=8BWR5xr2rU82cb35QZYsLw","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:07:20+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"NBC12","url":"http:\/\/www.nbc12.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/702\/normal\/Screen_Shot_2016-01-26_at_14.51.21.png?1453819926"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565027421&p=1pl&v=1&x=Gn3d_5Ke-hTpABdIvNzQXA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KTEN","url":"http:\/\/www.kten.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/643\/normal\/Screen_Shot_2016-01-26_at_11.36.58.png?1453808251"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565042419&p=1pl&v=1&x=6T8gQo6ZAx_8DvZYyrJtCA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:09:34+00:00","summary":"-- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom, May 17, 2016 \/PRNewswire\/ -\u2026","author":{"name":"Benzinga","url":"http:\/\/www.benzinga.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/738\/normal\/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565146835&p=1pl&v=1&x=PeST3FFEWBE4OJPiyb7Gag","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T16:08:10+00:00","summary":"CHESTERFIELD, United Kingdom, May 17, 2016 \/PRNewswire\/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565046597&p=1pl&v=1&x=1oWYjWr5rZQCegRxatylzQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:01:00+00:00","summary":"-- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom, May 17, 2016 \/PRNewswire\/ -\u2026","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565049394&p=1pl&v=1&x=Z0hj1zJe_fqdrPtVtNGL3g","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:10:25+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KX News","url":"http:\/\/www.kxnet.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/650\/normal\/Screen_Shot_2016-01-26_at_11.58.45.png?1453809587"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565056998&p=1pl&v=1&x=NtbsRTgZVuDGp78UMMBe3w","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WTVM","url":"http:\/\/www.wtvm.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/646\/normal\/Screen_Shot_2016-02-02_at_14.58.13.png?1454425111"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565063991&p=1pl&v=1&x=SZXhuIW8MLFuI76E9kbA0g","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"NBC Right Now KNDU 25","url":"http:\/\/www.nbcrightnow.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/735\/normal\/Screen_Shot_2016-01-26_at_15.54.16.png?1453823699"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565067463&p=1pl&v=1&x=aM8QVb_7LZyMqTsyT5bThA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:12:27+00:00","summary":"\/PRNewswire\/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P.","author":{"name":"Stockhouse","url":"http:\/\/www.stockhouse.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/768\/normal\/Screen_Shot_2016-01-26_at_16.49.41.png?1453827072"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565080904&p=1pl&v=1&x=6JL-iRm733TYuUPMpSa6Fw","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:14:03+00:00","summary":"\/PRNewswire\/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P.","author":{"name":"Ariva","url":"http:\/\/www.ariva.de","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/907\/normal\/Screen_Shot_2016-01-27_at_14.41.07.png?1453905685"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565087599&p=1pl&v=1&x=Xug_DoBfcHMvgX0ff3TQCA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:01:00+00:00","summary":"\/PRNewswire\/ -- Mallinckrodt plc ( MNK ), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P.","author":{"name":"Yahoo! Finance Singapore","url":"http:\/\/sg.finance.yahoo.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/721\/normal\/Screen_Shot_2016-01-26_at_15.33.41.png?1453822448"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565091047&p=1pl&v=1&x=-dS26C4sYIA4zJjqfCXmAg","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:15:10+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"Fox Wilmington","url":"http:\/\/www.wsfx.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/740\/normal\/Screen_Shot_2016-01-26_at_16.09.52.png?1453824618"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565127045&p=1pl&v=1&x=ScR6s4IFSBvfi2lESwcQAg","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KFVE The Home Team","url":"http:\/\/www.k5thehometeam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/734\/normal\/Screen_Shot_2016-01-26_at_15.53.15.png?1453823633"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565135424&p=1pl&v=1&x=67kBy4ujoogn1B5JPlcKTA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"Fox 14 News","url":"http:\/\/www.fox14tv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/651\/normal\/Screen_Shot_2016-01-26_at_12.00.07.png?1453809650"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565137639&p=1pl&v=1&x=97bUp809WIrF08c9tSE1mQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"NewsWest9","url":"http:\/\/www.newswest9.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/703\/normal\/Screen_Shot_2016-01-26_at_14.52.45.png?1453820009"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565152142&p=1pl&v=1&x=N2fnY-4JgOWWT6fGrG0ssQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WLOX","url":"http:\/\/www.wlox.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/657\/normal\/Screen_Shot_2016-01-26_at_12.08.48.png?1453810156"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565161809&p=1pl&v=1&x=uQnKT5SxoZ8KPIjOqemsAw","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:23:03+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KUSI News","url":"http:\/\/www.kusi.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/663\/normal\/Screen_Shot_2016-01-26_at_13.26.05.png?1453815145"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565165721&p=1pl&v=1&x=c7F2uCnmLvnmUs7f0NfuJg","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:23:32+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"NewsOn6","url":"http:\/\/www.newson6.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/677\/normal\/Screen_Shot_2016-01-26_at_14.12.15.png?1453817572"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565187672&p=1pl&v=1&x=PzkavI6bsr_IgjDQkOxcUg","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:26:13+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WLTZ","url":"http:\/\/www.wltz.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/653\/normal\/Screen_Shot_2016-01-26_at_12.04.16.png?1453809879"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565189523&p=1pl&v=1&x=gVKpWoJ1s1lKnUxS1uR7Sw","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:26:26+00:00","summary":"Mallinckrodt plc (via noodls) \/ CHESTERFIELD, United Kingdom, May 17, 2016 \/PRNewswire\/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4\u2026","author":{"name":"Noodls","url":"http:\/\/www.noodls.com\/index.asp","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/955\/normal\/Screen_Shot_2016-02-11_at_11.48.48.png?1455191394"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565204677&p=1pl&v=1&x=6547teHRke3inMNHygJpag","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KLKN-TV Eyewitness News","url":"http:\/\/www.klkntv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/655\/normal\/Screen_Shot_2016-01-26_at_12.06.08.png?1453810028"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565207880&p=1pl&v=1&x=duR9qgXQ0ve60okiwMzAmQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WISTV","url":"http:\/\/www.wistv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/689\/normal\/Screen_Shot_2016-01-26_at_14.30.56.png?1453818748"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565226888&p=1pl&v=1&x=mJ_Hq5Lx7C4fuZC52F2tcA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"ABC 6 News WLNE","url":"http:\/\/www.abc6.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/712\/normal\/Screen_Shot_2016-01-26_at_15.16.08.png?1453821391"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565228893&p=1pl&v=1&x=ljRIFyfgq7RFtEBqu_x1gA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:30:32+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WDAM - TV","url":"http:\/\/www.wdam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/682\/normal\/Screen_Shot_2016-01-26_at_14.19.46.png?1453818016"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565243696&p=1pl&v=1&x=gvxX262eViJwlNBkfzm6rQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:31:40+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"Kuam","url":"http:\/\/www.kuam.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/667\/normal\/Screen_Shot_2016-01-26_at_13.48.34.png?1453816300"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565244974&p=1pl&v=1&x=jRz7Zp8pgXjVheaTEGbyvA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"Cleveland 19","url":"http:\/\/www.cleveland19.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/683\/normal\/Screen_Shot_2016-01-26_at_14.20.50.png?1453818081"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565310825&p=1pl&v=1&x=CuCnuxVouCxDRF7LRFNDzA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KLTV","url":"http:\/\/www.kltv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/704\/normal\/Screen_Shot_2016-01-26_at_14.54.15.png?1453820113"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565317829&p=1pl&v=1&x=y6DPEvOiUGfRLav6sd5ruA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"CW: Richmond","url":"http:\/\/www.cwrichmond.tv","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/648\/normal\/Screen_Shot_2016-01-26_at_11.48.33.png?1453809040"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565320188&p=1pl&v=1&x=HrJ86NvkyL5xGHSnm6z7TA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:39:46+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WBOC 16","url":"http:\/\/www.wboc.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/717\/normal\/Screen_Shot_2016-01-26_at_15.23.21.png?1453821908"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565324142&p=1pl&v=1&x=fgTRwDJ2_1XdtEA-Jlf18g","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KPLC 7 News","url":"http:\/\/www.kplctv.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/641\/normal\/Screen_Shot_2016-01-26_at_11.30.17.png?1453807834"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565333330&p=1pl&v=1&x=yx9mq1iMsVUEoo_FzukQcg","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"48 WAFF","url":"http:\/\/www.waff.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/699\/normal\/Screen_Shot_2016-01-26_at_14.47.41.png?1453819680"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565342343&p=1pl&v=1&x=eiZqehcfci_ZYzpbwaQvIg","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:41:58+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KCENG12","url":"http:\/\/www.kcentv.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/642\/normal\/Screen_Shot_2016-01-26_at_11.32.50.png?1453808008"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565350894&p=1pl&v=1&x=WHsG1QnlTwa3lRL-CAhnSg","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WFLX Fox 29","url":"http:\/\/www.wflx.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/656\/normal\/Screen_Shot_2016-01-26_at_12.07.36.png?1453810094"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565393582&p=1pl&v=1&x=-lRioaShWHi3_O2trzw4sQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:47:54+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KSLA News 12","url":"http:\/\/www.ksla.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/709\/normal\/Screen_Shot_2016-01-26_at_15.10.50.png?1453821079"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565402358&p=1pl&v=1&x=wtX0TBtbTNM37t_c-j4QOg","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:48:48+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"CBS8","url":"http:\/\/www.cbs8.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/681\/normal\/Screen_Shot_2016-01-26_at_14.17.19.png?1453817863"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565402892&p=1pl&v=1&x=xn0tkW4M-Jmtiw3laIXngg","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WRCB- TV","url":"http:\/\/www.wrcbtv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/690\/normal\/Screen_Shot_2016-01-26_at_14.32.42.png?1453818828"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565447830&p=1pl&v=1&x=x0uLBu0oZi_eUNpVlEZzew","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WSFA ","url":"http:\/\/www.wsfa.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/644\/normal\/Screen_Shot_2016-01-26_at_11.40.39.png?1453808470"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565449961&p=1pl&v=1&x=5glnt--ISjNgzO-yyWKMJQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"Erie News Now","url":"http:\/\/www.erienewsnow.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/707\/normal\/Screen_Shot_2016-01-26_at_15.07.51.png?1453820898"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565470317&p=1pl&v=1&x=13uyhzTWT6iurjmrzVUQ7g","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:56:54+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"14 News","url":"http:\/\/www.14news.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/696\/normal\/Screen_Shot_2016-01-26_at_14.43.50.png?1453819462"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565517042&p=1pl&v=1&x=lWXbYCV53n6aMuhJ8GsUiA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T21:01:55+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WDRB","url":"http:\/\/www.wdrb.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/693\/normal\/Screen_Shot_2016-01-26_at_14.37.05.png?1453819066"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565517923&p=1pl&v=1&x=iaRuL9jgfli7aUe55nR41w","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"News Channel","url":"http:\/\/www.kxxv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/645\/normal\/Screen_Shot_2016-01-26_at_11.42.27.png?1453808595"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565565977&p=1pl&v=1&x=c9X3U8rstRDL0lmOTV6vHw","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T21:06:29+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"12 News KBMT","url":"http:\/\/www.12newsnow.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/731\/normal\/Screen_Shot_2016-01-26_at_15.48.47.png?1453823371"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565569205&p=1pl&v=1&x=xn4hPme6PWzE3cJM2D00pQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T21:06:52+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KHQ","url":"http:\/\/www.khq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/658\/normal\/Screen_Shot_2016-01-26_at_12.10.14.png?1453810239"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565573299&p=1pl&v=1&x=TFESqrgPD6X0Ap30Ar5FVw","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T21:07:19+00:00","summary":"\/PRNewswire\/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P.","author":{"name":"BioTech Gate","url":"http:\/\/www.biotechgate.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/835\/normal\/Screen_Shot_2016-01-27_at_11.07.21.png?1453892866"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565602729&p=1pl&v=1&x=ltFCZj6A6gxMbGspeMzXUw","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KAIT-TV","url":"http:\/\/www.kait8.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/672\/normal\/Screen_Shot_2016-01-26_at_14.02.53.png?1453817085"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565641258&p=1pl&v=1&x=xwLvzgDdewjQN-TUkOK_IA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T21:14:49+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"Hawaii News Now","url":"http:\/\/www.hawaiinewsnow.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/661\/normal\/Screen_Shot_2016-01-26_at_12.16.42.png?1453810633"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565685970&p=1pl&v=1&x=akS3J59-MxE_j0ojDP67yw","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T21:20:09+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KTRE","url":"http:\/\/www.ktre.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/705\/normal\/Screen_Shot_2016-01-26_at_15.04.21.png?1453820750"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565799667&p=1pl&v=1&x=GnVAcp0UloHhv0XIOO5kCQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"Mississippi News Now ","url":"http:\/\/www.msnewsnow.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/649\/normal\/Screen_Shot_2016-01-26_at_11.57.00.png?1453809440"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565825616&p=1pl&v=1&x=XPhJAIy9tUGiASkiejiZpA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WMBF News","url":"http:\/\/www.wmbfnews.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/710\/normal\/Screen_Shot_2016-01-26_at_15.11.39.png?1453821128"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565838662&p=1pl&v=1&x=aNPBqDJRNKIvHJkj_9dkZw","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"KiiiTV 3 ","url":"http:\/\/www.kiiitv.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/715\/normal\/Screen_Shot_2016-01-26_at_15.19.51.png?1453821626"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565881837&p=1pl&v=1&x=Mjz_ZRvmCZIa0aTmjE7R2Q","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"ABC 40","url":"http:\/\/www.abc40.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/698\/normal\/Screen_Shot_2016-01-26_at_14.45.46.png?1453819612"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565891029&p=1pl&v=1&x=OZ6ms4h9y2nZRiS0_PvWAA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T21:43:49+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WFMJ","url":"http:\/\/www.wfmj.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/701\/normal\/Screen_Shot_2016-01-26_at_14.49.34.png?1453819812"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565908371&p=1pl&v=1&x=Z7E0y7VlhxI5VAIdyfVrGA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WALB","url":"http:\/\/www.walb.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/647\/normal\/Screen_Shot_2016-01-26_at_11.47.02.png?1453808851"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565919358&p=1pl&v=1&x=ser4NsONJAx-4BTrXb8obw","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"South Carolina News Now","url":"http:\/\/www.live5news.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/730\/normal\/Screen_Shot_2016-01-26_at_15.47.02.png?1453823263"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565923331&p=1pl&v=1&x=lu39XT75D1ALYcUnwz032g","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T21:47:39+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WTOC","url":"http:\/\/www.wtoc.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/688\/normal\/Screen_Shot_2016-01-26_at_14.30.16.png?1453818642"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565928742&p=1pl&v=1&x=XWjxtWW8uYJF_F0S5NJt9A","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"WMC Action News 5","url":"http:\/\/www.wmcactionnews5.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/727\/normal\/Screen_Shot_2016-01-26_at_15.42.23.png?1453822987"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565941844&p=1pl&v=1&x=Iuce1Mbbr0OHqVArnYuv5g","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T21:50:04+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"Wave 3 News","url":"http:\/\/www.wave3.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/697\/normal\/Screen_Shot_2016-01-26_at_14.44.55.png?1453819521"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26565955239&p=1pl&v=1&x=XJJnAj6fV8RLvPlT9Qdd3A","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"2 News","url":"http:\/\/www.ktvn.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/654\/normal\/Screen_Shot_2016-01-26_at_12.05.19.png?1453809947"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26566125528&p=1pl&v=1&x=EvfDF4bER7Sbh9PoKvEGPg","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"News Channel 6","url":"http:\/\/www.newschannel6now.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/652\/normal\/Screen_Shot_2016-01-26_at_12.01.23.png?1453809711"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26566134977&p=1pl&v=1&x=NL9fdIaya3QS-BJE6PXV7w","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T22:12:09+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"ABC 7 News KSWO","url":"http:\/\/www.kswo.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/708\/normal\/Screen_Shot_2016-01-26_at_15.08.58.png?1453821021"}},{"title":"First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar\u00ae Gel for Rare Cause of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26566464002&p=1pl&v=1&x=tKuwF05RcXsD129TGkq2YQ","license":"public","citation_ids":[7562353],"posted_on":"2016-05-17T20:04:00+00:00","summary":"SOURCE Mallinckrodt -- Mallinckrodt's PODOCYTE Trial to Assess Efficacy of Acthar for the Treatment of Proteinuria in Treatment-Resistant or Treatment-Intolerant Idiopathic Focal Segmental Glomerulosclerosis -- CHESTERFIELD, United Kingdom \"This\u2026","author":{"name":"News 9","url":"http:\/\/www.news9.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/691\/normal\/Screen_Shot_2016-01-26_at_14.34.55.png?1453818924"}},{"title":"First Patient Enrolled In Mallinckrodt Phase 4 Trial Of H.P. Acthar Gel For Rare Cause Of Nephrotic Syndrome","url":"http:\/\/ct.moreover.com\/?a=26573289277&p=1pl&v=1&x=IpWLB82Akv5auFWNezgqMA","license":"public","citation_ids":[7562353],"posted_on":"2016-05-18T00:00:00+00:00","summary":"\/PRNewswire\/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P.","author":{"name":"Biospace","url":"http:\/\/www.biospace.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/375\/normal\/biospace.png?1437140433"}}]}}